Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Belantamab Mafodotin for Multiple Myeloma
Recruiting1 awardPhase 1
Detroit, Michigan
This trial is testing a new drug to treat MM. The drug is given intravenously once every 3 weeks. The trial will last up to 48 months and will test the safety, tolerability, and pharmacokinetics of the drug in MM patients with different levels of renal impairment.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service